Stock Taper 
| DATE | TYPE | RATIO |
|---|---|---|
| 2026-08-31 | Reverse | 1:30 |
Nexalin Technology, Inc. develops non-invasive neurostimulation devices for mental health treatment, including anxiety, insomnia, and other disorders, with products marketed in the U.S. and China.
The Gen-3 HALO Clarity is a non-invasive, at-home neurostimulation headset that delivers proprietary waveforms to deep brain areas for drug-free mental health treatment, supporting Nexalin's virtual clinic model with remote monitoring and personal...
On October 8, 2025, Nexalin Technology, Inc. announced it had received a U.S. patent for its HALO Clarity device, which utilizes Deep Intracranial Frequency Stimulation for mental wellness applications. This news was a major catalyst, causing the company's stock to surge dramatically and putting a spotlight on its non-invasive mental health treatment technology.
In a formal letter to shareholders, Nexalin Technology's leadership identified the pursuit of CE Mark approval for its Gen-3 Halo device as a critical strategic priority for 2025. This move is intended to enable the company's entry into the European market, representing a pivotal step in its global expansion strategy to make its neurostimulation technology more widely available.
Agreement establishes an initial 100-device commercialization program for the ANVISA-approved Nexalin Sync™ across seven countries and more than 300 million people, with a structured pricing framework and a mechanism for larger strategic transactions with government and private-sector customers
Appointment as Senior Strategic Advisor marks the Company's expansion from clinical development toward commercialization of its DIFS™ platform in the United States, Europe and South America DiTota spent over two decades in neuromodulation at Abbott and Medtronic, two of the largest companies in the field, including responsibility for Abbott's North America commercial neuromodulation business, a division representing approxim ately $700 million in business Nexalin's Gen-2 SYNC device is already approved in China, Brazil, Oman and Israel; the engagement is intended to build the distribution relationships, go-to-market plan and commercial infrastructure required to convert those approvals into commercial sales HOUSTON, TX, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), developer of non-invasive Deep Intracranial Frequency Stimulation (DIFS™) technology, today announced the appointment of Robert DiTota as Senior Strategic Advisor, Global Commercialization, effective September 15, 2026.
Overall rating: D+
| PEER | PRICE | |
|---|---|---|
 NRXS | $7.23 | COMPARE |
 HBIO | $8.71 | COMPARE |
 SCYX | $5.04 | COMPARE |
 MODD | $2.33 | COMPARE |
 XCUR | $1.07 | COMPARE |
 ENLV | $0.37 | COMPARE |
 CLGN | $3.48 | COMPARE |
 RBOT | $0.07 | COMPARE |
